ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

AVCT Avacta Group Plc

49.75
0.75 (1.53%)
Last Updated: 16:13:35
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Avacta Group Plc LSE:AVCT London Ordinary Share GB00BYYW9G87 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.75 1.53% 49.75 49.50 50.00 49.75 47.50 48.75 2,736,093 16:13:35
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 10.06M -39.19M -0.1382 -3.60 141.1M

Avacta Group PLC Affimers in Scientific Publications

24/10/2017 7:00am

RNS Non-Regulatory


TIDMAVCT

Avacta Group PLC

24 October 2017

24 October 2017

Avacta Group plc

("Avacta","the Group" or "the Company")

Record Year for Affimers in Scientific Publications

Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and reagents, is pleased to announce that 2017 has been a record year for scientific publications using Affimer reagents, with nine scientific papers reporting the work of leading groups world-wide.

Two recent papers from the world-renowned laboratory of David Komander at the University of Cambridge have been published in two important international journals - Molecular Cell, and Nature Structural & Molecular Biology. These research articles describe the use of Affimer reagents that recognise important cell signals called the "diubiquitin linkages", which are thought to be involved in a wide range of diseases. Affimers have been generated that are specific to two of the diubiquitin linkages, for which no antibodies exist and the work has revealed hitherto unknown biology.

Another powerful example of the broad utility of Affimer binders, as research and diagnostic reagents, was a paper in the journal eLife from a group at the University of Leeds, in collaboration with numerous other scientists around the world. In this paper, the performance of Affimer reagents that bind to twelve different targets was compared with antibodies across seven different applications. The paper showcases the key benefits of Affimer technology: high target specificity, intracellular activity, small size and wide target range.

The interest that a scientific paper generates is assessed by the tracking web site Altmetric. Altmetric ranks the attention that the Affimer paper in eLife received, as being in the top 5% of all the 8.4 million papers ever tracked.

Dr Alastair Smith, Avacta Group Chief Executive Officer, commented:

"Independent scientific reports featuring Affimer reagents are strong validations of the technology and highly influential indirect marketing. During 2017, nine Affimer scientific papers have been published, compared with two in 2016 and four in 2015, and are being read by an ever widening audience; a strong indication of the growing awareness and adoption of the Affimer technology.

"As well as being a bumper year for Affimer publications, it is particularly pleasing to see reports of Affimers' key benefits in the most prestigious scientific journals and I look forward to seeing this trend continue in 2018."

For further information from Avacta Group plc, please contact:

 
 Avacta Group plc                        Tel: +44 (0) 
  Alastair Smith, Chief Executive         844 414 0452 
  Officer                                 www.avacta.com 
  Tony Gardiner, Chief Financial 
  Officer 
 finnCap Ltd                             Tel: +44 (0) 
  Geoff Nash / Giles Rolls - Nominated    207 220 0500 
  Adviser                                 www.finncap.com 
  Tim Redfern / Alice Lane / Nikita 
  Jain - Corporate Broking 
                                          Tel: +44 (0) 
  WG Partners                             203 705 9318 
  Nigel Birks / Nigel Barnes              Tel: +44 (0) 
  David Wilson / Claes Spang              203 705 9217 
                                          www.wgpartners.co.uk 
 Zyme Communications (Trade and          Tel: +44 (0)7787 
  Regional Media)                         502 947 
  Katie Odgaard                           katie.odgaard@zymecommunications.com 
 
  Yellow Jersey (Financial Media          Tel: +44 (0)7764 
  and IR)                                 947137 
  Sarah Hollins                           avacta@yellowjerseypr.com 
 

About Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer(R) technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAUORRRBUARUAA

(END) Dow Jones Newswires

October 24, 2017 02:00 ET (06:00 GMT)

1 Year Avacta Chart

1 Year Avacta Chart

1 Month Avacta Chart

1 Month Avacta Chart

Your Recent History

Delayed Upgrade Clock